middle.news
Radiopharm Theranostics Secures Key Supply Deal for Prostate Cancer Trial
9:45am on Tuesday 24th of June, 2025 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Secures Key Supply Deal for Prostate Cancer Trial
9:45am on Tuesday 24th of June, 2025 AEST
Key Points
Supply agreement signed with Cyclotek for radiolabelling RAD 402 with Terbium-161
RAD 402 targets KLK3, highly expressed in prostate cancer cells
Preclinical data confirms safety and promising biodistribution profile
Phase 1 clinical trial anticipated to start in second half of 2025 in Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE